Heart rate variability-based prediction of early cardiotoxicity in breast-cancer patients treated with anthracyclines and trastuzumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Heart rate variability-based prediction of early cardiotoxicity in breast-cancer patients treated with anthracyclines and trastuzumab ; volume:10 ; number:1 ; day:29 ; month:5 ; year:2024 ; pages:1-14 ; date:12.2024
Cardio-Oncology ; 10, Heft 1 (29.5.2024), 1-14, 12.2024
- Urheber
-
Luna-Alcala, Santiago
Espejel-Guzmán, Adrián
Lerma, Claudia
Leon, Paula
Guerra, Enrique C.
Fernández, Jose Rodrigo Espinosa
Martinez-Dominguez, Pavel
Serrano-Roman, Javier
Cabello-Ganem, Aldo
Aparicio-Ortiz, Alexis D.
Keirns, Candace
Lerma, Abel
Ana-Bayona, Maria Jose Santa
Espinola-Zavaleta, Nilda
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40959-024-00236-y
- URN
-
urn:nbn:de:101:1-2408062103197.449035009961
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Luna-Alcala, Santiago
- Espejel-Guzmán, Adrián
- Lerma, Claudia
- Leon, Paula
- Guerra, Enrique C.
- Fernández, Jose Rodrigo Espinosa
- Martinez-Dominguez, Pavel
- Serrano-Roman, Javier
- Cabello-Ganem, Aldo
- Aparicio-Ortiz, Alexis D.
- Keirns, Candace
- Lerma, Abel
- Ana-Bayona, Maria Jose Santa
- Espinola-Zavaleta, Nilda
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Exploring an novel diagnostic gene of trastuzumab-induced cardiotoxicity based on bioinformatics and machine learning
The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity
Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Exploring an novel diagnostic gene of trastuzumab-induced cardiotoxicity based on bioinformatics and machine learning
The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity
Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Exploring an novel diagnostic gene of trastuzumab-induced cardiotoxicity based on bioinformatics and machine learning
The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity